Patents by Inventor Houcine Rahali
Houcine Rahali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363707Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: November 17, 2022Applicants: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
-
Patent number: 10736908Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: October 20, 2017Date of Patent: August 11, 2020Assignees: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLCInventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
-
Patent number: 10519159Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: December 20, 2017Date of Patent: December 31, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals, LLC.Inventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
-
Patent number: 10513534Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: GrantFiled: October 7, 2013Date of Patent: December 24, 2019Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Gilles Gosselin, Christophe Claude Parsy, Francois-Rene Alexandre, Houcine Rahali, Jean-Francois Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
-
Patent number: 10449208Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: GrantFiled: August 22, 2017Date of Patent: October 22, 2019Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
-
Publication number: 20190262365Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: October 20, 2017Publication date: August 29, 2019Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
-
Publication number: 20190183912Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: August 22, 2017Publication date: June 20, 2019Applicants: Merck Sharp & Dohme Corp., IDENIX PHARMACEUTICALS LLCInventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
-
Publication number: 20180258130Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 16, 2018Publication date: September 13, 2018Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
-
Publication number: 20180179208Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS.Type: ApplicationFiled: December 20, 2017Publication date: June 28, 2018Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLCInventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
-
Patent number: 9296778Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: GrantFiled: May 21, 2013Date of Patent: March 29, 2016Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et TechniquesInventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
-
Publication number: 20160083413Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: ApplicationFiled: October 22, 2015Publication date: March 24, 2016Inventors: Gilles Gosselin, Christophe Claude Parsy, François-René Alexandre, Houcine Rahali, Jean-François Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart, David Dukhan
-
Publication number: 20160002281Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
-
Patent number: 9187496Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: GrantFiled: November 13, 2012Date of Patent: November 17, 2015Assignee: Idenix Pharmaceuticals LLCInventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
-
Publication number: 20140099283Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.Type: ApplicationFiled: October 7, 2013Publication date: April 10, 2014Inventors: Gilles GOSSELIN, Christophe Claude PARSY, Francois-Rene ALEXANDRE, Houcine RAHALI, Jean-Francois GRIFFON, Julien MILHAU, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Adel M. MOUSSA, Benjamin Alexander MAYES
-
Publication number: 20130315867Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Cyril B. DOUSSON, David DUKHAN, Gilles GOSSELIN, Houcine RAHALI, Dominique SURLERAUX
-
Patent number: 8426437Abstract: The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.Type: GrantFiled: June 30, 2006Date of Patent: April 23, 2013Assignee: Pierre Fabre MedicamentInventors: Hugues Bienayme, Antoine Dumoulin, Serge Grisoni, Bachir Kaloun El, Stephane Poigny, Remi Rabot, Rachid Rahali, Eric Tam, Pascaline Klein, Karim Bedjeguelal, Houcine Rahali
-
Patent number: 8362068Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: GrantFiled: December 17, 2010Date of Patent: January 29, 2013Assignee: Idenix Pharmaceuticals, Inc.Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
-
Publication number: 20120252721Abstract: Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.Type: ApplicationFiled: March 29, 2012Publication date: October 4, 2012Applicant: IDENIX PHARMACEUTICALS, INC.Inventors: Cyril B. Dousson, David Dukhan, John P. Billelo, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
-
Publication number: 20110150827Abstract: Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Applicant: Idenix Pharmaceuticals, Inc.Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy, Claire Pierra, Francois-Rene Alexandre, Guillaume Brandt, Daniel Da Costa, Houcine Rahali, Jean-Laurent Paparin, Michel Derock, Thierry Convard, Dominique Surleraux
-
Publication number: 20090042876Abstract: The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.Type: ApplicationFiled: June 30, 2006Publication date: February 12, 2009Applicant: Pierre Fabre MedicamentInventors: Hugues Bienayme, Antoine Dumoulin, Serge Grisoni, Bachir Kaloun El, Stephane Poigny, Remi Rabot, Rachid Rahali, Eric Tam, Pascaline Klein, Karim Bedjeguelal, Houcine Rahali